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Abstract
Background: Trials of risk estimation in breast cancer screening programmes, in order to identify women at higher
risk and offer extra screening/preventive measures, are ongoing. It may also be feasible to introduce less frequent
screening for women at low-risk of breast cancer. This study aimed to establish views of women at low-risk of
breast cancer regarding the acceptability of extending breast screening intervals for low-risk women beyond 3 y.
Methods: Semi-structured interviews were used to explore views of low-risk women, where “low-risk” was defined
as less than 2% estimated 10-year risk of breast cancer aged > 46 years. Low-risk women were identified via the BC-
Predict study, where following routine screening, women were given their 10-year risk of breast cancer by letter,
along with additional information explaining breast cancer risk factors. To gain diversity of views, purposive
sampling by ethnicity and socioeconomic background was used to recruit women. Data were analysed using
thematic analysis.
Results: Twenty-three women participated in individual interviews. Three themes are reported: (1) A good
opportunity to receive risk estimation, where women found it worthwhile to receive a low-risk result although some
were surprised if expecting a higher risk result; (2) Multi-faceted acceptability of extended screening intervals, with
reactions to less frequent screening dependent on whether women were confident in being low-risk status and
current safety evidence, (3) Passive approval versus informed choice, highlighting that women found it difficult to
consider choosing less frequent screening without professionals’ recommendations, as they generally viewed
attending breast screening as positive.
Conclusions: Risk assessment and receiving a low-risk of breast cancer is acceptable although, further research is
required with more diverse samples of women. Any recommendation of less frequent screening in this risk group
should be evidence-based in order to be acceptable. Communication needs to be carefully developed, with a focus
on ensuring informed choice, prior to trialling any extended screening recommendations in future studies.
Keywords: Breast cancer, Risk assessment, Risk-stratification, Acceptability, Screening, Mammography, Risk
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Background
The UK NHS Breast Screening Programme (NHSBSP)
invites women 3-yearly from age 50–70 years [1]. This
has not been without controversy, centring on whether
such programmes reduce overall mortality or burden of
treatment from early detection [2, 3] and whether this
outweighs harms. Specifically, screening programmes
may detect cancers that would have never become symp-
tomatic to require treatment i.e., overdiagnosis/over-
treatment [4] or lead to false positive screening test
results [5], with lasting psychological impact [6]. Given
this controversy, efforts have been made to clearly com-
municate about these potential harms and benefits of
screening [7]. Despite this, a recent review concluded
that women tend to view the benefits of breast screening
as outweighing the harms, and many misunderstand the
concept of overdiagnosis [8].
There are specific UK national guidelines to offer
additional screening to women at higher risk of breast
cancer [9]. However, only around 1 in 6 women at
moderate/high-risk of breast cancer have a family history
(FH) of the disease consistent with NICE FH criteria,
identified generally when women present to primary
care and are referred to family history, risk and preven-
tion clinics [10]. The use of risk estimation models (for
example, Tyrer-Cuzick) allows 5-year, 10-year or lifetime
breast cancer risk to be calculated in a timely manner,
and thereby identify these moderate/high-risk women
[11, 12]. Given this, interventions to systematically
identify women at higher risk of breast cancer as part of
routine breast screening, are currently being evaluated
[13, 14]. For example, the BC-Predict intervention
provides feedback to women according to four risk cat-
egories: below average (or low), average, above average
(or moderate) and high.
Although much of the impetus for risk-stratified
screening comes from the potential to identify high risk
women and offer them prevention and early detection
options, discussion about the implementation of a risk-
stratified breast cancer screening programme (BCSP) has
led to consideration of whether it is safe to reduce screen-
ing for women at low-risk. Not only are such women by
definition less likely to develop cancer, they are also less
likely to develop faster growing, high-grade tumours [15].
Ensuring women understand the harms and benefits of a
risk-stratified BCSP, where screening invite frequency
could be reduced for those low-risk, is arguably even more
important should it be introduced more widely. UK
professionals involved in national screening programme
policy decision-making and breast screening programme
service delivery reported acceptability of extended breast
screening intervals for low-risk women in principle,
although identified key implementation issues, including
obtaining acceptability from women [16, 17].
Although previous surveys indicate women think risk-
stratified breast screening is a good idea, the samples
were more accepting of additional screening if high-risk
than less frequent screening if low-risk [18, 19]. How-
ever, it was unclear why women were less willing to
accept this. Although previous qualitative studies have
discussed risk-stratified breast cancer screening with
women of breast screening age [20–22], there appears to
be no published research directly exploring the views of
women with a low-risk estimate. This is notable, as if ex-
tending the screening interval is unacceptable to the af-
fected population, it would be difficult for this change to
be feasible. The present study therefore aimed to elicit
the views of women at low-risk about receiving this in-




A cross-sectional, qualitative design using semi-
structured interviews was employed. Women were iden-
tified from an on-going study investigating breast
screening risk stratification, BC-Predict [14], and had
consented to be approached about future research. In
BC-Predict, women were invited to find out their 10-
year risk of breast cancer as part of routine breast
screening. Consenting BC-Predict participants complete
a self-report risk estimation questionnaire (online or
paper) and approximately 6-weeks later (if the partici-
pant has received a clear mammogram result), receive
written feedback based on information they provided
about known breast cancer risk factors and breast dens-
ity calculated from their mammogram images.
Procedure
Women were invited by post to participate in an inter-
view between 23 and 246 days after having received their
BC-Predict risk feedback. Only women with a 10-year
risk estimate of < 2% were invited to participate i.e., low-
risk. To recruit a diverse sample, up to two additional
reminder letters were posted to women who self-
reported Black and Minority Ethnic Refugee ethnicity or
had an Index of Multiple Deprivation (IMD) [23] decile
of below 5 (1 indicates the most deprived and 10, the
least).
Interviews took place in participants’ homes, in a quiet
room (university or hospital), or by telephone. All
interviews were conducted by two female researchers
with post-graduate experience conducting qualitative
research. With consent, they were audio-recorded,
transcribed verbatim and each woman assigned a
pseudonym. Data collection continued until research
team members (LM, VGW, DPF) agreed there was suffi-
cient data to answer the research aim [24].
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Materials
To develop an interview topic guide, women ap-
proaching the age at which they would be invited by
the NHSBSP reviewed a draft topic guide based on a
review of relevant literature and, findings from previ-
ous interviews conducted with national screening fig-
ures [16] and screening professionals [17]. Feedback
on wording and order of questions were incorporated
and refined. The final version (Additional file 1) fo-
cused on asking women about their experience par-
ticipating in BC-Predict, receiving a low-risk breast
cancer estimate, views about reducing the screening
frequency for low-risk women (including decision-
making, communication and information needs) and,
understanding of the harms and benefits of breast
screening. The guide was used flexibly in each inter-
view to follow up ideas and thoughts introduced by
participants.
Analysis
Interview data was analysed using reflexive thematic
analysis from a critical realist perspective, based on the
reality of the data and acknowledging the researchers’
role in analysis [25]. Transcripts were read, re-read and
audio-files listened to with initial notes captured, before
manifest-level, inductive coding using Nvivo 11 soft-
ware. Two transcripts were double-coded (LM, VGW)
and any discrepancies discussed and resolved as the it-
erative coding framework developed (LM). Coding was
used to generate candidate themes compared across the
data set and continually discussed (LM, VGW, DPF)
before refinement. The final thematic structure was




Of 83 women invited, 26 indicated interest and 23 took
part. Interviews lasted 33 to 107min (median 68min),
with three conducted by telephone and 20 face-to-face.
Fourteen women took part following their first BCSP
invite. For additional sample details, see Table 1.
Three themes were produced: (1) A good oppor-
tunity to receive risk estimation, (2) Multi-faceted
acceptability of extended screening intervals and (3)
Passive acceptance versus informed choice. Quotes
are presented with a pseudonym followed by each
participant’s age bracket.
Theme 1: a good opportunity to receive risk estimation
The sample revealed how they felt about being at low-risk
of breast cancer as part of breast screening, were able to
describe what it meant personally and, how this impacted
on their views about extended screening intervals.
Reactions to personal risk estimates: two sides of the same coin
All women reflected on receiving a low breast cancer
risk estimate positively, although many could not re-
member exact contents of feedback letters. Understand-
ing the different contributions of risk factors largely
underpinned how women interpreted the feedback and,
whether they expected their result. Where women were
surprised, they had expected their family history or other
risk factors (e.g., not having children) to contribute to
receiving a higher estimate and questioned the accuracy
of risk assessment. Others wondered how the different
risk factors are weighted and on two occasions, women
described providing risk information as difficult.
…what’s not clear from the information, is how much
that prediction is based on the actual mammogram
results and how much is based on what you completed
in your questionnaire Erinma;45-54
Table 1 Sample characteristics







Asian or Asian British: Indian 1
White European 1
Black or Black British: African 1
Mixed: White & Black African 1
Education
A levels or equivalent 2




Index of Multiple Deprivation Decile









10 (least deprived) 1
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Overall, women explained that their results provided a
sense of relief and for many, ‘one less thing’ to worry
about. In one account, a woman described her risk as
helpful when deciding about medication for menopausal
symptoms.
I kind of felt more reassured about going onto [Hor-
mone replacement therapy] HRT because of the pre-
diction said low [...] going on HRT may not be that
bad because although it may be only an increase of
one in a 100 people, women, who get breast cancer
from being on HRT, I’m already at a low level.
Shelagh;45-54
Minimising complacency
Due mainly to receiving validation of how they already
felt, some women were somewhat dismissive re-counting
the experience as not having much impact …perhaps
you don’t take it in so much because it’s not a direct im-
mediate threat to your own health (Emma;45–54). Des-
pite this, many recognised that receiving low-risk breast
cancer estimates does not mean that they will never be
diagnosed and although helpful information to receive,
expressed realistic views that they could still be diag-
nosed with breast cancer. Subsequently, most voiced in-
tentions to maintain healthy lifestyles, attend future
screening and remain breast aware.
It means that, sort of, lifestyle, things that have…you
know, things that have happened in the past
genetically, I’m probably at a lower risk of getting
breast cancer, but anyone can get it still. It could
happen at any time so it’s not that I’m never going
to get it, it’s just that I’m at, sort of, the low risk end
of the scale of likely to get it. Annie;45-54
Cautiously positive about extended intervals
Initial reactions to the idea of less frequent screening were
positive, or neutral, across most of the sample. Women
who did not expect to receive a low-risk estimate, and who
wanted to know more about the stability of their risk, were
more apprehensive when discussing longer screening inter-
vals. Several questioned whether longer intervals are being
considered for cost cutting reasons, rather than safety. This
concern led to some expecting a backlash from women
feeling entitled to remain on 3-yearly intervals.
Actually, the truth of the matter is I think I’d rather feel
a bit miffed about it […] my immediate reaction would
be ‘it’s a money saving’ […] Maybe I’m being cynical, but
I take it as being a money saving device. Violet;65-74
In contrast, assuming that longer screening intervals
would allow those at higher risk of breast cancer to be
offered more screening, others viewed the proposal al-
truistically, as a better use of national funding. Regard-
less of viewpoints, women wanted to know more
about why less frequent screening for low-risk should
be introduced.
…it’s just me using my brain isn’t it? They’re at
greater risk; give them the chance to have it caught
early and then if somebody doesn’t have to go
through full blown chemotherapy and maybe can
just potentially have radio [therapy]. Enriquetta;45-
54
Theme 2: multi-faceted acceptability of extended
screening intervals
Women considered what breast screening could look
like if low-risk women were offered less frequent screen-
ing and, thoughts were generally based on their opinions
about current breast screening. This was challenging for
women to discuss without having previously thought
much about how screening programmes are generally
organised.
Screening means security
Despite being largely accepting of the possibility of less
frequent breast screening, women viewed the current 3-
yearly programme favourably overall. Some women ac-
knowledged that interval cancers and false positives
already exist within 3-yearly screening however, con-
cerns about having fewer mammograms related to a loss
of safety that breast cancer will be detected quickly.
Women often cited present life circumstances, or know-
ing individuals who have experienced cancer, as reasons
to continue with 3-yearly screening invites.
…at my age now I’d feel a duty towards my family,
my children, that I should go through treatment and
that’s how I feel […] really catching any cancer early
would be important to me, as most people, I guess,
but especially the younger you are. Maxine;45-54
Therefore, in spite of being given information that
those at low-risk could be less likely to be diagnosed
with ‘aggressive’ breast cancer, women were worried that
longer intervals would result in later stage cancer diag-
noses. Communication about longer screening intervals,
emphasising the importance of self-examination with a ‘I
am low risk, there’s no history in the family, but it doesn’t
mean to say I’ll never get it’ (Elizabeth;55–64) approach,
was expected to minimise interpreting the change as li-
cense to ignore breast health. On two occasions, women
highlighted the need for a clear rationale from experts to
minimise contradicting the early detection agenda initia-
tives aimed at improving screening uptake.
McWilliams et al. BMC Cancer          (2021) 21:637 Page 4 of 9
…you are very much encouraged to go for any
screening that’s available and I think knowing what
kind of breast cancer can involve in treatment and
things like that. Lydia;45-54
Improvements in life expectancy led some to state that
the upper age limit (70 or 73 years) is no longer fit for
purpose and, introducing low-risk screening provides
opportunity for reviewing the entire programme.
…people are living longer and it used to be that
people died between 50 and 70…shift everybody
along a bit. Eleanor;65-74
A reasonable screening length
All women discussed what screening interval length
could be offered, with quite varied opinions. Everyone
felt there should be some screening once low-risk has
been established. However, many were unsure what the
current interval or invite age range is and how these
were decided. It was quite difficult for women to elicit a
specific interval although expected it to be underpinned
by evidence.
I would kind of assume that lots and lots of research
and thinking had gone on behind all of that, it
wouldn’t just be a magic figure plucked from thin
air. Ellen;45-54
When prompted by the interviewer, an interval of 5
years was viewed most positively although, many were un-
able to articulate why; 10 years seemed too long for most.
Some women referenced age-adapted cervical screening
intervals to explain their views and often highlighted they
have not questioned the lengths in this programme.
Others felt a change should not be too drastic as women
are already experiencing health changes.
I suppose it seems like a big gap to me, six years
seems quite a lot […] I’m currently going through the
menopause, and the amount of physical change that
has happened over the last year is quite staggering.
Marie;45-54
A number of women wondered whether low-risk
screening frequencies would be different depending on
age and whether risk could change over time. Reason-
ing conflicted relating to perceptions that older women
are at greater risk but, breast cancer diagnoses would
have a greater negative impact on younger women.
Given that risk assessments would identify higher risk
women (to offer more frequent screening), two women
suggested risk-stratified screening should start earlier
than age 50-years.
…instead of waiting until 50 you’re almost selling it
as a, ‘we’re actually going to screen you early’ […]at
45 and then every five years after that, unless the
risk changes Victoria;45-54
Theme 3: passive approval versus informed choice
When asked how they would decide whether to opt for
longer screening intervals, women identified the limits of
ensuring informed choice within screening as felt un-
accustomed to deliberate about how much they interact
with such programmes. This led women to expect that
guidance from healthcare professionals in the field
would be provided.
Individual decision-making is challenging
Deciding whether to accept longer screening intervals
was often difficult for women to consider. Many women
could not remember the harms (i.e., overdiagnosis and
false positives) and benefits of breast screening provided
with their invite and, most viewed false positives as good
in order to rule out cancer.
I mean I wasn’t aware that there was any deleterious
effect from the actual screening process. So under those
circumstances I think I’d probably prefer to carry on
being screened. Emmeline;65-74
Whether it is possible to implement a ‘strict’ longer
screening interval, where women are not offered choice,
influenced many women’s thoughts about longer inter-
vals. Knowing they could easily re-access screening with
suspected symptoms, and be taken seriously, were as-
sumed by many:
…if I was to feel something that I’m not used to
within my body, just because my screening is in five
years, I don’t have to wait for five years, I can go to
the GP and say, 'look, this is not comfortable', the
GP will refer […] It’s not, like, 'this is it, we’ve set it
in stone' and it cannot be changed. Clara;45-54
Regardless, when asked what decision they would make
if it were a choice, several women initially ‘on the fence’
when first discussing longer intervals, reported that they
would be ‘quite happy to have it every three years’ (Carol;
45–54) for reassurance. In one account, a woman viewed
it as unfair to not be allowed to make her own decision
despite acknowledging that the cervical screening interval
changes depending on age. However, others wanted to be
told how frequently they should attend mammograms as
would feel unable to decide on their own:
I’m a natural born worrier, so I then think back to
the research that says, 'well it might be more
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harmful to have them more frequently'. Then I’d be
torn as to, 'oh what do I do, it could be more harm-
ful to have them every three years?' […] Or, what if
I’m the one that’s low risk and does get cancer? I’m
the one that’s low risk and gets a false positive be-
cause I’ve been going every three years? Lucy;45-54
Desire for guidance from professionals
Given the complexities women highlighted when consid-
ering how they would opt for extended screening intervals,
provided a clear, evidence-based explanation was given,
the majority described feeling accepting of the idea that
less frequent screening for low-risk might be introduced.
…if the NHS feel confident in giving that advice then
I would feel confident in taking because you are a
trusted supplier of messages. Joanne;55-64
Without having been able to review evidence demon-
strating the safety of less frequent screening, one woman
explicitly disagreed with this.
So if they automatically said every five years I’d
probably be a bit annoyed, just because there is going
to be a percentage of people who do get it. Not annoyed,
but I’d be a bit worried. If I was given the choice and
made my own decision based on more accurate details
and facts and then that would be my decision, rather
than every three years, then I’d be happier with that
than just being told ‘you’re in that category, we’re going
for every five years’. Caroline;45-54
Women viewed the proposal as placing greater respon-
sibility on women for their breast health therefore, a num-
ber identified a default longer interval with the ability to
opt back in to 3-yearly intervals could improve acceptabil-
ity; one woman suggested this could be temporary ‘…
maybe that for a period of transition might be the solution
rather than having a big outcry of women being deprived
mammograms (Jackie;45–54). However several wondered
if this would be possible financially.
Is it a good use of resources? I mean if it turns out
that a larger number of women want to stay on the
three-year cycle and yet professionally it’s not
considered necessary, it’s a tricky one. […] If it were
very low numbers, it wouldn't matter too much. But
it doesn't seem right to be offering some expensive
procedures or whatever when they are not medically
necessary. Ethel;65-74
Discussion
Overall, women felt generally positive about breast
cancer risk being assessed as part of routine breast
screening and receiving a low-risk estimate. Less fre-
quent screening for women at low-risk appeared accept-
able, as long as safety evidence is available and is not
only due to saving money. Women did not believe
screening should stop altogether for this group and indi-
cated an interval length not too dissimilar to the current
3-yearly programme could be appropriate. It was diffi-
cult for most women to think about deciding to choose
a longer interval; most wanted guidance from expert
health professionals. Women appeared to base their
views about the acceptability of less frequent screening
on their experience of others having breast cancer, their
understanding of the BCSP and how they currently
interact with screening.
Women appreciated the chance to receive their 10-
year risk of breast cancer and the majority were pleased
with receiving a low-risk estimate. This is in line with
findings of a previous quantitative study that found that
women told they were at lower risk felt less cancer
worry and general anxiety than other women [26]. How-
ever, some women were less convinced by their result
had they expected to receive a higher risk or, were un-
sure they had been able to provide adequate information
to allow accurate risk estimates to be produced. This
generally underpinned how women reacted to the idea
of having less frequent breast screening based on these
estimates. Consistent with previous research focusing on
extending screening for women at low-risk of breast
cancer [16, 17] and studies exploring risk-stratified
breast screening as a whole [21, 27], women sought evi-
dence that demonstrated the safety, including whether
estimates are accurate and stable over time. Although
evidence illustrates the accuracy of 10-year breast cancer
risk models for predicting cancer [28], how much these
risk estimates change for individuals is poorly understood.
Although balanced information is likely to be included
in invites to breast screening, women with positive atti-
tudes towards cervical screening downplay the harms
[29], so it is not surprising women in this study did so
when almost the entire sample viewed breast screening
positively. Similarly, it was to be expected that women
hesitate to identify a longer screening interval length for
those at low-risk as concepts such as overdiagnosis are
largely difficult to comprehend [30]. In the present
study, many questioned why the current interval is 3-
years, suggesting a general passive acceptance of screen-
ing invites. Women found it difficult to consider making
a decision about whether to have less frequent screening
or, opt for the current 3-yearly interval, with some sug-
gesting they would remain on 3-years just in case. This
echoes previous research indicating that although risk-
stratified breast screening was viewed positively by
women who have not participated in breast cancer risk
assessment, there was less enthusiasm for reduced
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screening if low-risk [18, 20]. Previous research has
shown American and Australian women have suspicions
that breast screening programme changes are under-
pinned by money-saving efforts [31, 32]. However, some
considered less frequent screening altruistically where
resources could be re-allocated to those in greater need,
which may be based on the number of women who cited
others affected by the disease.
Strengths and limitations
The study explored views about risk-stratified breast
screening from women who with a low 10-year breast
cancer risk estimate; other research has focussed on
women with average or above risk. Recruitment methods
aimed to ensure a diverse sample from an ethnicity and
socioeconomic perspective but, were limited by those
eligible from the BC-Predict study. Over 80% of the
eligible sample were of White British background,
reflecting the current study sample however, the recruit-
ment approaches used may not have been the optimal
method of engaging with non-White groups of women.
The median IMD decile (five) for the sample interviewed
matched that of BC-Predict women invited to the study
and, recruitment rates were slightly higher (29%) for
women living in areas with an IMD ranging from 1 to 5
than those living in less deprived areas (24% for IMD
range 6–10). Women who took part were, on the whole,
highly educated and were willing to have their breast
cancer risk assessed. It could be that this sample are par-
ticularly interested in breast cancer risk and could be
more accepting of extended screening intervals however,
the interview topic guide was open allowing positive and
negative views to be expressed. Due to the lack of ethnic
diversity within both the recruited sample and BC-
Predict, it may be that non-White women have particu-
lar views about the acceptability of breast cancer risk
assessment as well as less frequent screening for women
at low-risk.
Implications
Any risk-stratified screening approach where screening is
reduced for low-risk women should clearly explain the ra-
tionale and supporting evidence given that having adequate
knowledge partly underpins informed choice [33]. Some
women were concerned that the proposal was financially-
based. Despite reservations, the women appeared generally
trusting that a publically funded programme would only
recommend this change if appropriate to do so. Communi-
cation around such changes to breast screening, that could
be considered de-implementation of a service, should
however be carefully handled especially to minimise
misunderstanding, as highlighted in interviews with UK
screening figures and screening professionals [16, 17]. In
addition, communication materials should be developed in
consideration of the ethnic diversity of the population likely
to be invited given that previous research identified that
British-Pakistani women were enthusiastic about risk-
stratified screening [34] although described barriers to at-
tending the NHSBSP including lack of knowledge about
breast screening [35].
Further research is required to assess how women
might respond to a recommendation of extending BCSP
screening intervals in receipt of a low 10-year breast
cancer risk estimate. Views from women who do not
currently adhere to screening recommendations i.e., in-
vited to the BCSP but do not attend for a mammogram,
should be obtained to determine whether risk-stratified
screening may be more or less acceptable if a low-risk
pathway is introduced. This is particularly important
given the high educational attainment of the present
sample as evidence suggests lower uptake and poorer
understanding of risk is associated with socioeconomic
status, such as qualifications [36]. Future research should
be conducted with women from diverse backgrounds as
although previous research highlighted that British-
Pakistani women were interested in breast cancer risk
assessment, including many where English was a second
language, views may vary across other ethnic groups [34].
Conclusions
The findings have demonstrated that it is acceptable to
receive a low-risk breast cancer estimate as part of breast
screening, from the perspective of a generally well edu-
cated, mainly White British sample. Several challenges
were highlighted in ensuring informed choice should
risk-stratified screening approaches to breast cancer
screening introduce less frequent screening for women
identified at low-risk of breast cancer.
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